Results 151 to 160 of about 742,291 (286)

PARP Inhibitors as Radiosensitizers: Current Evidence and Future Directions. [PDF]

Curr Oncol Rep
Pereira E, Pereira F, Campos G, Abrantes AM, Botelho MF, Silva-Vaz P, Pires AS.   +6 more
europepmc   +1 more source

PARP inhibitors during conception and pregnancy in breast cancer

Approximately 1 in 10 women diagnosed with breast cancer before the age of 35 carry germline BRCA pathogenic/likely pathogenic variants. Poly (ADP-ribose) polymerase (PARP) inhibitors have been recently approved in the treatment of both early and ...
Zagouri, Flora, Dimopoulos, Meletios-Athanasios, Andrikopoulou, Angeliki   +2 more
core  

Precision medicine in cancer: A comprehensive review of advanced cancer diagnosis technologies and personalized treatment strategies

Precision Medical Sciences, EarlyView.
The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan, Bushra Waheed, Rani Akbar, Daniel Dubwa   +3 more
wiley   +1 more source

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors. [PDF]

RSC Adv
Rani D, Plebanski M, Chatterjee T.
europepmc   +1 more source

Real‐World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON‐3 Study

The Prostate, EarlyView.
ABSTRACT Background Homologous recombination repair (HRR) testing is increasingly relevant in prostate cancer because it identifies patients who may benefit from biomarker‐guided treatment strategies, including poly(ADP‐ribose) polymerase inhibitors (PARPi).
Lorena Incorvaia, Veronica Mollica, Ondřej Fiala, Kazutoshi Fujita, Yüksel Ürün, Bohuslav Melichar, Javier Molina‐Cerrillo, Teresa Alonso‐Gordoa, Umberto Basso, Maria T. Bourlon, Emmanuel Seront, Ugo De Giorgi, Maria José Juan Fita, Pasquale Rescigno, Tarek Taha, Fernando C. Maluf, Alexandr Poprach, Simona De Summa, Tomas Buchler, Luca Galli, Jindrich Kopecky, Gaetano Aurilio, Jakub Kucharz, Carlo Messina, Gabriel Berlingieri Polho, Sarah Scagliarini, Francesco Grillone, Diogo Assed Bastos, Luigi Formisano, Gian Paolo Spinelli, Alessandra Mosca, Alessandro Rizzo, Aristotelis Bamias, Fernando Sabino Marques Monteiro, Andrey Soares, Francesco Massari, Andrew J. Armstrong, Matteo Santoni   +37 more
wiley   +1 more source

Mechanisms of resistance to PARP inhibitors in advanced epithelial ovarian cancer: biological determinants and therapeutic implications. [PDF]

Front Oncol
Incognito D, Ciappina G, Ettore G, Ettore C, Incognito GG, Carroccio P, Esposito E, D'Arienzo A, Barraco C, Donato M, Cianci S, Busà B, Di Mauro G, Berretta M.   +13 more
europepmc   +1 more source

Molecular Basis for Uracil‐DNA‐Glycosylase to Identify DNA Damage in the Nucleosome

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT The DNA base‐excision repair (BER) pathway is initiated by a glycosylase, such as uracil‐DNA‐glycosylase (UDG), which identifies and removes a wrong base incorporated in the DNA sequence. The very early steps in the identification of the DNA damage are crucial to the correct initiation of the repair chain, and become even more complex when ...
Safwen Ghediri, Ralf Blossey, Fabrizio Cleri   +2 more
wiley   +1 more source

Brassinin Inhibits Cell Survival and Autophagy via Modulation of ROS Production and the AMPKα‐beclin1 Signaling Pathway in Gliomas

Phytotherapy Research, EarlyView.
Brassinin, a phytoalexin derived primarily from Chinese cabbage, exhibits potent anticancer activity against glioblastoma (GBM). Mechanistically, brassinin treatment elevates intracellular ROS levels in GBM cells, triggering two parallel outcomes: (i) direct induction of apoptosis, and (ii) suppression of cytoprotective autophagy through downregulation
Sunil Rauniyar, Yuhui Wang, Qiaoshan Zhang, Shicheng Zhang, Jiale Yin, Tong Zhang, Shangfeng Gao, Rutong Yu   +7 more
wiley   +1 more source

Ruta graveolens L. in Evidence‐Based Phytotherapy: Pharmacological Activities, Bioactive Compounds and Safety

Phytotherapy Research, EarlyView.
Graphical representation of ethnomedical uses, major bioactive compounds, pharmacological potential and toxicological risks of Ruta graveolens L. ABSTRACT Ruta graveolens L. is widely used in traditional European, Asian, African, and South American medicine for digestive, nervous, cardiovascular, respiratory, and reproductive disorders.
Tetiana Serhiienko, Victoriya Georgiyants, Liudas Ivanauskas, Olha Mykhailenko   +3 more
wiley   +1 more source

Loss of CHTF18-RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors. [PDF]

NAR Cancer
Buckley-Benbow L, Ozgencil M, Tardocchi A, Agnarelli A, Bellelli R.   +4 more
europepmc   +1 more source